Targeting of Liposomes via PSGL1 for Enhanced Tumor Accumulation
- First online:
To improve the delivery of liposomes to tumors using P-selectin glycoprotein ligand 1 (PSGL1) mediated binding to selectin molecules, which are upregulated on tumorassociated endothelium.
PSGL1 was orientated and presented on the surface of liposomes to achieve optimal selectin binding using a novel streptavidin-protein G linker molecule. Loading of PSGL1 liposomes with luciferin allowed their binding to e-selectin and activated HUVEC to be quantified in vitro and their stability, pharmacokinetics and tumor accumulation to be tested in vivo using murine models.
PSGL1 liposomes showed 5-fold (p < 0.05) greater selectin binding than identically formulated control liposomes modified with ligand that did not contain the selectin binding domain. When added to HUVEC, PSGL1 liposomes showed >7-fold (p < 0.001) greater attachment than control liposomes. In in vivo studies PSGL1 liposomes showed similar stability and circulation to control liposomes but demonstrated a >3-fold enhancement in the level of delivery to tumors (p < 0.05).
The technologies and strategies described here may contribute to clinical improvements in the selectivity and efficacy of liposomal drug delivery agents.
KEY WORDSdrug delivery liposome PSGL1 selectin tumor
immunoglobulin fragment crystallizable region
horse radish peroxidise
human umbilical cord venous endothelial cells
P-selectin glycoprotein ligand 1
Actively targeting drug loaded liposomes to surface receptors up-regulated on tumor cells should improve anti-tumor efficacy. However, despite the assistance provided by the enhanced permeability retention effect (1) there are still many limitations to achieving such targeting. The high interstitial pressure and dense extracellular matrix within tumors (2), makes penetration beyond the perivascular region inefficient (3–5), thereby lowering the opportunity for interaction between targeted liposomes and target cells. Furthermore the receptors available as targets often lack the desired specificity or presentation on tumor cells and show variable expression between different cancer types.
In response to these limitations, targeting therapeutics to the endothelial cells which support tumors has emerged as an attractive alternative strategy. In contrast to normal endothelium, tumor-associated endothelial cells have an inflamed phenotype due to activation by cytokines produced by the tumor (6). This pro-inflammatory activation promotes increased proliferation and results in up-regulated levels of cell surface receptors such as αvβ3 integrins, vascular endothelial growth factor receptors, vascular cell adhesion proteins and selectins (7–10). The properties and surface receptor expression profiles of tumor-associated endothelium are common amongst patients with the same type of cancer (11) and amongst different types of cancer (12–14), and yet still distinct from normal endothelium. Therefore, targeting these receptors should enable the development of therapeutics which are active against a wide range of cancer types whilst maintaining their selectivity for tumor-associated rather than normal endothelium. It is also noteworthy that intravenously delivered therapeutics have rapid and direct contact with tumor-associated endothelium.
Targeting to selectins expressed on endothelial cells is a particularly attractive strategy. Selectins are a family of calcium dependent type-I transmembrane protein comprised of: platelet (P)-selectin (expressed on endothelial cells as well as platelets), endothelium (E)-selectin and leukocyte (L)-selectin. P and E-selectin play a crucial role in recruitment of leukocytes to inflamed endothelium, a process which takes place despite the presence of shear flow and multiple other bloodstream components. This is possible because selectin mediated binding triggers a mechanism of ‘rolling’ and slowing of leukocytes (15,16). Selectins may therefore be ideal target receptors as their physiological role so closely matches the requirements needed to achieve efficient binding of blood borne therapeutic agents to the tumor-associated endothelium. Indeed, success in achieving selectin mediated endothelial targeting in pre-clinical models has been previously reported for viral and non-viral gene delivery vectors (15,16). It is notable that in these reports care was taken to ensure that correct ligand presentation and orientation were achieved to permit optimal receptor binding. The application of protein A or G has allowed antibodies or ligands bearing the Fc domain of immunoglobulin to be linked to therapeutics with high affinity whilst preserving receptor binding regions (17,18). Similar strategies have also been reported utilising the even higher affinity interaction between bungarotoxin and its ligand (19).
Here we report the first in vivo use of P-selectin glycoprotein ligand 1 (PSGL1) to enhance the targeting of liposomes to tumor endothelium. We demonstrate that by designing a novel conjugation strategy which presents PSGL1 on the surface of the liposome in the correct orientation specific binding to endothelial cells in vitro and enhancements in tumor accumulation in vivo can be achieved.
MATERIALS AND METHODS
Hydrogenated soy phosphatidylcholine (HSPC, 840058) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[biotinyl(polyethyleneglycol)-2000] (DSPE-PEG-Biotin, 880129) were purchased from Avanti Polar Lipids (USA). Cholesterol (C8667), Streptavidin (S4762) and protein G (19459) were purchased from Sigma (UK). Biotinylated-horse radish peroxidise (43-2040) was purchased from Invitrogen (CA, USA). Goat IgG-horse radish peroxidise (12348) was purchased from Millipore (UK). Fc linked PSGL1 (3345-PS) and the control Fc lacking the PSGL1 domain (110-HG) were purchased from R and D Systems (UK). Human Umbilical Vein Endothelial cells (HUVECs; PromoCell, Germany) were maintained in EGMTM-2-Endothelial Cell Medium-2 (Cambrex Bio Science, USA), supplemented with hydrocortisone, h-FGF-B, VEGF, R3-IGF-1, ascorbic acid, heparin, FBS, hEGF, and GA-1000 (Cambrex Bio Science, USA). E-selectin was purchased from R and D systems. E1, E3-deleted Ad5 expressing cytomegalovirus immediate-early (CMVIE) promoter-driven luciferase (Adluc) was purchased from Hybrid Biosystems Ltd (UK). D-Luciferin and B16-F10-luc cells were purchased from Caliper life sciences (USA) and maintained as recommended by the manufacturer.
Formulation of Liposomes and Luciferin Loading
Liposomes were formulated by mixing HSPC, cholesterol and DSPE-PEG or DSPE-PEG-biotin at ratios of 55:40:5 in 2 chloroform: 1 methanol, in a round bottomed flask. After complete dissolution rotary evaporation for 30 min at 55°C achieved a thin film which after drying under high vacuum overnight was rehydrated in 300 mM Tris pH 10 for 60 min. Sizing was achieved by extrusion at 55°C using a LiposoFast extruder (purchased from GC technology Ltd, UK) with 11 passes through a 400 nm filter (86-039) followed by a 11 passes through a 100 nm (86-037) filter. Buffer exchange into 25 mM citrate, 150 mM NaCl buffer pH 5 using a PD10 column (GE healthcare) created a trans-bilayer pH gradient which was used to actively load luciferin dissolved in 25 mM citrate, 150 mM NaCl buffer. After incubation of 1.8 mL of 20 mg/mL liposomes with luciferin (30 mg in 100 μL) overnight at room temperature, non-loaded luciferin was removed and buffer exchanged for phosphate buffered saline. Luciferin loading was calculated by the addition of a 1:1 mix of buffer containing free recombinant luciferase (25 mM HEPES, 2 mM EDTA, 60 μg/mL BSA, 40 μg/mL DTT, 20 μg/mL luciferase (Sigma, F3776), pH 7.5) and an ATP buffer (25 mM HEPES, 2 mM EDTA, 1 mM ATP, pH 7.5). Measurements were taken in a luminometer (Berthold, LB9507) following heating sample to 100°C for 5 min or not and compared to a standard curve of identically treated dilutions of free luciferin. The percentage of encapsulated luciferin was calculated by the formula ((μg post heating – μg pre-heating) / μg post heating) × 100. After purification and buffer exchange into PBS using a PD column the percentage of encapsulated luciferin was found to be in excess of 97%. Dynamic light scattering was performed using a Malvern Zetasizer 3000 (Malvern Instruments), with 3 sub-runs of 10 and automatic analysis, on 3 separate samples.
Formulation and Testing of a Protein G-Streptavidin Linker and Addition to Liposomes
Streptavidin was modified with protein G at a range of ratios using EDC chemistry as modified from (20). Streptavidin 0.1 mg was dissolved in 100 μL (final conc 0.013 mM) of 0.1 M MES (2-[morpholino]ethanesulfonic acid), 0.1 M NaCl, buffer pH 5.6 and 10 μL 0.04 mg (2.5 mM final conc), of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrocholoride (EDC, Pierce) and Sulfo-NHS (1 mg, 5 mM final conc) was then added and after 15 min at room temperature buffer pH was raised using PBS. Protein G was then added at a range of ratios for 2 h at room temperature, as defined in figure legends. Analysis of changes to protein size and ligand binding ability was performed using SDSPAGE with Coomassie staining or transfer onto nitrocellulose and blotting with biotinylated-horse radish peroxidise (HRP) (Invitrogen) or Fc-HRP (Millipore) in 5% milk/PBS for 1 h, followed by 3 × 10 min washes in PBS/Tween 0.01%. Nitrocellulose was developed with ECL reagent (GE Healthcare) and images captured and densiometrically analysed using an Alpha Innotech imager and FluorChemHD2 software. The ratio which gave optimal maintenance of binding to both Fc and biotin was identified (1 streptavidin : 2 protein G) and used for addition to luciferin loaded liposomes incorporating PEG-biotin (see Formulation of Liposomes and Luciferin Loading). After incubation overnight excess protein G-streptavidin was removed by separation on a PD10 column (GE healthcare).
In Vitro Assays of Binding to Selectins
Maxisorb ELISA plates (Nunc) were coated with E-selectin (R and D systems) as described by (21). Optimisation and confirmation of coating was provided using a BCA assay (Sigma). E-selectin (50 μg/mL), dissolved in PBS was added 50 μL/well overnight at 4°C, then removed before blocking with 100 μL PBS/1% bovine serum albumin for 1 h at room temperature. After three washes in 200 μL of PBS, 50 μL of luciferin loaded Fc-control or PSGL1 liposomes in PBS was added per well for 30 min at room temperature. Sample was then removed and 10 washes in 200 μL of PBS performed. 200 μL of PBS was placed in each well and the plate heated to 70°C degrees. Sample was transferred into luminometer tubes, luciferase/ATP was added as in Formulation of Liposomes section and measurement performed using a luminometer (Berthold, LB9507). For assaying binding to HUVEC, cells were plated at 10,000 per well in a black 96 well plate. To achieve luciferase expression in the HUVECs so that the binding of luciferin loaded liposome could be assayed the cells were infected with an adenovirus vector expressing the luciferase transgene (Adluc). After 24 h, 500 of particles of Adluc were added per cell for 90 min before washing and returning to the incubator overnight. Liposomes (2 μL per well) were then added in 100 μL fresh media. The luciferase/luciferin signal was then assayed at 5, 10, 20 and 60 min using a Wallac 1420 plate reader. 5 × washes in 100 μL PBS were then performed and media was replaced and incubation and measurement continued for the next 27 h. Experiments were performed with n = 4, results were typical of three separate experiments and analysis of significance was obtained using ANOVA comparisons and PRISM software.
In Vivo Analysis of Release, Circulation, and Tumor Accumulation
B16-F10-luciferase cells were grown and implanted (5 × 105 cells) into the flank of C57 Bl6 mice. After 3 weeks when tumors had reached a size of between 500 and 700 mm3 their luciferase expression was confirmed and compared by injecting 100 μL of 15.8 mg/mL of free luciferin in PBS intravenously and imaging after 5 min using an IVIS 100 (Caliper Life Sciences, USA). 2 days later mice were re-imaged to verify their return to background luminescence levels and then 80 μL liposomes / 280 μg of luciferin sample was injected intravenously. IVIS images and blood samples (20 μL) were taken at 15, 30, 60 and 120 min after injection after which time mice were culled and organs harvested for quantification of biodistribution and tumor accumulation. Samples were lysed and heated and luciferin content calculated against standard curves made with identically processed organs from untreated mice which had been spiked with serial dilutions of known amounts of luciferin loaded liposomes. Heating was demonstrated to both release still encapsulated luciferin and destroy endogenous tumor luciferase. Organ and blood associated luciferin could therefore be calculated by the addition of luciferase/ATP as in Formulation of Liposomes section. Data shown were typical of two experiments. Analysis was performed by ANOVA using PRISM.
Protein G-Streptavidin Conjugates with Ligand Binding Properties of Both Sub-Units
PSGL1 Modification of Liposomes for Selectin and HUVEC Binding
The interaction between the enzyme luciferase and its substrate luciferin produces dose dependent quantifiable photon emissions. Loading of liposomes with luciferin therefore enabled their binding to selectin coated plates to be assayed with great sensitivity (see Materials and Methods). Following a 1 h incubation with liposomes and thorough washing with PBS, binding was quantified by heating the plate to release luciferin which was then added to recombinant luciferase enzyme and assayed by luminometry. PSGL1 liposomes showed 5-fold (p < 0.05) greater binding to the selectin coated plates than control Fc-liposomes (Fig. 2b). This binding could be inhibited by pre-incubation of the plate with a 100-fold excess of free PSGL1.
The specific PSGL1 mediated targeting of liposomes was confirmed in studies using HUVEC expressing luciferase (Fig. 2c). After a period of 60 min to allow interaction between cells and liposomes, cells were thoroughly washed to remove any non-bound liposomes. During the subsequent 60 min no difference in luciferin luminescence, was observed for cells exposed to PSGL1 liposomes compared to those exposed to Fc control liposomes or non-modified liposomes, perhaps indicative of the need for a period to allow release of luciferin from PSGL1 liposomes bound to cells. However, from 3 h onwards cells exposed to PSGL1 liposomes started to produce significantly increased luminescence signal compared to controls, indicative of improved binding. This differential increased over time reaching 7-fold by 27 h (p < 0.001). In previous reports of in vitro selectin mediated targeting, binding required activation of the endothelial cells with tumour necrosis factorα (TNFα) (25). Notably the targeting observed in our studies was achieved without the addition of TNFα. This suggests that, in accordance with previous reports (26), the use of Adluc to achieve luciferase expression in these cells was a sufficient stimulus to also induce selectin presentation. In studies where delivery was compared with and without a 4 h pre-incubation with 100 ng/mL of TNFα, similar results to those in Fig. 2c were obtained (Fig. S2b). Exposure of HUVEC to Adluc or TNFα and probing with Fc-control or PSGL1 confirmed the presence and ligand binding functionality of selectins under these conditions (Fig. S2c).
In Vivo Testing of PSGL1 Liposomes
Post-cull analysis of tumor accumulation demonstrated that approximately 1.2% of the injected dose of PSGL1 liposomes had accumulated per gram of tumor (1.2% ID/g), during the 2 h following intravenous administration. This proved to be a significant (p < 0.05) and substantial (5-fold or 3.5-fold) increase compared non-modified liposomes or Fc-control liposomes (Fig. 4c). As all these liposome formulations demonstrated identical bloodstream stability and similar clearance profiles this increase is indicative of PSGL1 ligand providing increased association with tumor-associated endothelium. Probing of tumor cryosections with PSGL1 confirmed the presence of selectins on this endothelium (Fig. S3c). The level of tumor association of non-modified liposomes is in accordance with the levels reported in pre-clinical studies which have utilised radiolabelling to demonstrate that Doxil like formulations achieve 0.6% ID/g tumor after 18 h (29) or 0.2% ID/g tumor after 4 h (30). Recently a strategy for targeting liposomes directly to tumors achieved an impressive 4.7% ID/g of tumor after 48 h (31), an improvement over the level observed in our studies. This improvement may be due to the longer duration allowed before assaying and the enhanced ability to achieve efficient internalisation. The different characteristics of the target tumor models used may also be an important factor, as recently demonstrated by Ogawara et al. (32). The protein G-streptavidin ‘platform’ vector and in vivo test system we have developed could allow a vast range of Fc containing antibodies or fusion proteins to be directly compared, so that optimal targeting strategies, conditions and ligands could be identified. Although the high immunogenicity of streptavidin may limit its ultimate clinical application the optimal targeting ligands identified by these studies could be formulated as direct conjugates to the liposomes.
The advantages of targeting drug delivery to tumor-associated vasculature has long been recognised (33). Selectin molecules provide a particularly attractive target due to their upregulation on inflamed endothelium and the fact that their physiological role in leukocyte recruitment mimics that required to bind and slow drug delivery macromolecules under conditions of shear flow. As a result, several investigations using a variety of selectin ligands to target liposomes have been reported (34) (25) (35), with impressive in vitro results. Here we present the first demonstration that such targeting can improve tumor accumulation in in vivo studies performed using pre-clinical tumor bearing models. The reported difficulties of synthesising and using sialyl Lewis(X) (36) and our previous experience comparing anti-selectin antibodies to the PSGL1 ligand for retargeting of adenovirus vectors (17) persuaded us that the PSGL1 ligand would provide optimal ease of use, efficiency of targeting and reduced immunogenicity. Previous studies have also demonstrated the advantage of attaching targeting ligand to therapeutic agent in ways that use epitopes of the ligand that are not involved in receptor binding and achieve appropriate orientation of the ligand (37) (19). To meet this requirement we developed a new protein G-streptavidin biomaterial as a linker between biotin on the liposome surface and Fc regions in the PSGL1. This conjugate was produced by chemically cross-linking the two recombinant proteins. We believe the chemical conjugation strategy we employed to be the most efficient and assured method considered the challenges faced in trying to engineer and express recombinant streptavidin fusion proteins. Although the problems of inclusion body formation and inappropriate refolding of native streptavidin produced in E. coli have been overcome (38,39), in the case of fusion proteins the yield of correctly folded protein is often sub-optimal and a general refolding method has not been established. A sophisticated enzyme mediated approach to circumvent this problem and produce a GFP-streptavidin fusion protein has recently been published, but this has not yet been attempted for a protein G-streptavidin (40). Our optimised protein G-streptavidin linker demonstrated binding to both Fc domains and biotin (Fig. 1) and produced a ‘platform’ system that could be used to test the ability of any Fc bearing antibody or fusion protein to target liposomes. In our in vitro experiments substantial and significant increases in the attachment of liposomes to E-selectin and activated HUVEC was achieved using PSGL1 (Fig. 2). To date, there have been no reports testing the ability of selectin targeted liposomes to accumulate in tumor-associated endothelium in vivo, perhaps because such experiments fell outside the scope of previous studies. In our studies loading liposomes with luciferin allowed in vivo stability, pharmacokinetics and tumor accumulation to be sensitively and accurately measured (Fig 3 and 4). Liposomes targeted with PSGL1 showed similar stability and pharmacokinetics to non-targeted controls but demonstrated significantly and substantially increased accumulation in tumors. Levels obtained after just 2 h approached 1.2% of the injected dose per gram of tumor. PEGylated liposomes demonstrate good circulation and EPR assisted tumor accumulation, however their enhanced stability means that they achieve sub-optimal release of therapeutic cargo and poor penetration beyond the perivascular space (3). The application of ultrasound offers a method by which the targeted release of drug payload from such liposomes can be non-invasively triggered (41). This is an especially attractive strategy when combined with the delivery of microbubbles, which allows powerful ‘cavitation’ events to be generated at diagnostic ultrasound pressure (42). However, following co-delivery of liposomes and microbubbles the EPR effect will allow entry of liposomes (100–200 nm) into tumors whilst excluding microbubbles (~2.5 μm), and such partitioning will prevent the microbubbles impacting on the liposomes. By increasing accumulation of liposomes on the tumor-associated endothelium using PSGL1 targeting, it is hoped we can enhance the efficiency of microbubble/ultrasound-induced tumor-specific release of drug from liposomes. Our further studies will investigate the combination of these strategies for enhanced tumor therapy.
Here we describe the novel application of PSGL1 to liposomes to provide successful targeting to selectins. This was achieved by the chemical formulation of a novel biomaterial, a protein G-streptavidin conjugate, which retained the ligand binding activities of both its sub-units and could therefore act as a linker between liposomes and the PSGL1 molecule. The creation of this linker provides the opportunity to test a range of different ligands containing the immunoglobulin Fc region (antibodies, fusion proteins), using the same ‘platform’ protein G-streptavidin modified liposome formulation. This strategy has the advantage of linking ligands to liposomes via domains that are not involved in their interaction with cell surface receptors. Such optimal orientation and presentation proved beneficial in our studies using PSGL1 which provided substantial enhancements in selectin binding in vitro. The subsequent significant increases in tumor accumulation we observed using PSGL1 targeted liposomes in a pre-clinical xenograft model, suggests such a strategy may provide clinical improvements in the selectivity and efficacy of liposomal drug delivery agents.
ACKNOWLEDGMENTS AND DISCLOSURES
The authors would like to acknowledge generous financial support from the Engineering and Physical Sciences Research Council (EPSRC) of the United Kingdom (C.C.C.) under Challenging Engineering award EP/F011547/1, the Wellcome Trust & EPSRC under grant number WT088877/Z/09/Z (R.C.C) and Cancer Research UK (L.W.S.).
This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.